Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 28, 2017

Conditions
Multiple Sclerosis
Interventions
DRUG

4-aminopyridine

Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.

DRUG

Placebo

The placebo arm will include Microcrystalline Cellulose placebo

Trial Locations (1)

06725

Hospital de Especialidades, CMN Siglo XXI, Mexico City

All Listed Sponsors
lead

Coordinación de Investigación en Salud, Mexico

OTHER_GOV

NCT02280096 - Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter